血清抗dsDNA抗体联合IL-21、BCL6、CD71 mRNA水平对早期系统性红斑狼疮的诊断价值OA

Objective To investigate the clinical diagnostic value of anti-double-stranded(ds)DNA antibody combined with interleukin-21(IL-21),B-cell lymphoma 6(BCL6),and transferrin receptor(CD71)mRNA levels for early sys-temic lupus erythematosus(SLE).Methods Blood samples were collected from 41 newly diagnosed SLE patients(inclu-ding 8 in the active phase and 33 in the inactive phase)and 41 healthy controls between January 2021 and June 2025.Pe-ripheral blood mononuclear cells(PBMCs)were isolated,and the mRNA levels of IL-21,BCL6,and CD71 were meas-ured.Serum anti-dsDNA antibodies were detected by immunoblotting.Spearman correlation analysis was used to assess the relationship between the expression of the markers and the SLE disease activity index(SLEDAI)scores.Receiver operating characteristic(ROC)curve analysis was performed to evaluate the diagnostic efficacy of anti-dsDNA antibody combined with IL-21,BCL6,and CD71 gene expression for SLE.Results The levels of IL-21,BCL6,and CD71 in PBMCs were higher in SLE patients than in healthy controls(P＜0.05),and their expressions were elevated in active SLE patients com-pared to inactive patients(P＜0.0001).Spearman correlation analysis indicated that the expressions of these markers were positively correlated with SLEDAI scores(P＜0.01).The combination of anti-dsDNA antibodies and IL-21,BCL6,and CD71 genes achieved an area under the curve(AUC)of 0.952,with a sensitivity of 92.7％and specificity of 87.8％.Con-clusion The expressions of IL-21,BCL6,and CD71 genes are significantly elevated in SLE patients and positively corre-late with SLEDAI scores.Anti-dsDNA antibodies along with IL-21,BCL6,and CD71 gene expressions provide excellent diagnostic performance for early SLE.